Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN
Recruiting · NCT06690827 · Registry updated 2026-08-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, acute myeloid leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, myeloid leukemia, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2026-08-28 | NCT06690827 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chongqing Precision Biotech Co., Ltd | 34 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology. | Wuhan | China | 1 |